quinazolines has been researched along with clarithromycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Che, XF; Hiramoto, M; Ito, K; Miyazawa, K; Moriya, S; Sugita, S; Yamashiro, Y; Yokoyama, T | 1 |
| Che, XF; Handa, H; Hiramoto, M; Itoi, T; Kazama, H; Kokuba, H; Miyazawa, K; Moriya, S; Mukai, S; Ōmura, S; Sakamoto, S; Sugawara, A; Sunazuka, T; Yokoyama, T | 1 |
2 other study(ies) available for quinazolines and clarithromycin
| Article | Year |
|---|---|
EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2015 |
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.
Topics: Apoptosis; Autophagy; Azithromycin; Cell Line, Tumor; Clarithromycin; Drug Synergism; ErbB Receptors; Erythromycin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Pancreatic Neoplasms; Quinazolines | 2016 |